1 Report Overview
1.1 Global Human Microbiome Therapeutics Market Overview
1.2 Study Goals and Objectives
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.1 Key Questions Answered by This Analytical Report Include:
1.2 Who is This Report For?
1.3 Methodology
1.4.1 Primary Research
1.4.2 Secondary Research
1.4.3 Data Sources
1.4 Market Evaluation & Forecasting Methodology
1.5 COIVD-19 Impact Recovery Pattern Analysis
1.4.4 V-Shaped Recovery
1.4.5 U-Shaped Recovery
1.4.6 W-Shaped Recovery
1.4.7 L-Shaped Recovery
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2 Executive Summary
2.1 Key Take Away
3 Human Microbiome Therapeutics Products and Technology Overview
3.1 Introduction to Human Microbiome Therapeutics Products
3.1.1 The Human Microbiome
3.1.2 Gut Microbiome
3.1.3 Oral Microbiome
3.1.4 Skin Microbiome
3.2 Microbiome and Human Health and Disease
3.3 Essential Functions of Human Microbiome
3.4 Technologies Aiding Microbiome Research
3.5 Culturing and Cultivation
3.5.1 Animal Models
3.5.2 Gnotobiotic Animal Models
3.5.3 Engineered Systems
3.5.4 Organoid Cultures
3.5.5 Bioreactors
3.5.6 Microbiome Assaying
3.5.7 Direct Observation
3.5.8 Data Analysis
3.6 Microbiome Therapeutics Disease Areas
3.7 Regulatory Landscape for Microbiome Therapeutics
3.8 Microbiome Research Projects
4 Development of Microbiome Therapeutics
4.1 Additive Microbiome Therapy
4.2 Live Biotherapeutic Products (LBPs)
4.3 Modulatory Microbiome Therapy
4.3.1 Small Molecule Postbiotics
4.3.2 Prebiotics
4.4 Subtractive Microbiome Therapeutics
4.5 Antimicrobial Therapy
4.6 Phage Therapy
5 Market Dynamics
5.1 Overview
5.2 SWOT Analysis
5.3 Drivers of Microbiome Therapeutics Market
5.3.1 High Unmet Medical Need
5.3.2 Growing Understanding of the Microbiome
5.3.3 Positive Investment Environment
5.3.4 Strong Pipeline
5.3.5 Acceptance from Regulatory Authorities
5.4 Challenges for Microbiome Therapeutics Market
5.4.1 Lack of Regulatory Guidance
5.4.2 Product Characterization and Manufacturing Challenges
5.4.3 Hurdles in Preclinical and Clinical Research
5.4.4 Need for Skilled Labor
5.4.5 Emerging Markets
5.4.6 Development of Better Diagnostic Methods
5.4.7 Acquisitions and Partnerships
5.5 Threats to the Microbiome Therapeutics Market
5.5.1 New Government Regulations
5.5.2 Stiff Competition in the Global Market
5.5.3 COVID-19 Pandemic
6 Global Human Microbiome Therapeutics Market
6.1 Global Market Overview
6.2 Global Market Outlook in terms of Value (COVID-19 Impact Recovery Analysis)
6.3 Global Market Outlook by Region (COVID-19 Impact Recovery Analysis)
6.4 Global Market Outlook by Technology
6.4.1 Human Microbiome Therapeutics Technology Overview
6.4.2 Global Human Microbiome Therapeutics Market by Technology (Pre-COVID-19 Analysis)
6.4.3 Global Human Microbiome Therapeutics Market by Technology (Post-COVID-19 Impact Recovery Analysis)
6.5 Global Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
6.6 Global Market Outlook by Type
6.6.1 Fecal Microbiota Transplants (FMTs)
6.6.2 Live Biotherapeutic Products (LBPs)
6.6.3 Monoclonal Microbials
6.6.4 Engineered Bacteria
6.6.5 Modulatory Microbiome Therapeutics
6.6.6 Subtractive Microbiome Therapeutics
6.6.7 Global Market Outlook by Type (Pre-COVID-19 Analysis)
6.6.8 Global Market Outlook by Type (Post-COVID-19 Impact Recovery Analysis)
6.7 Global Market Outlook by Product (COVID-19 Impact Recovery Analysis)
7 North America Human Microbiome Therapeutics Market
7.1 North America Market Overview
7.2 North America Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.3 North America Market Outlook by Country (COVID-19 Impact Recovery Analysis)
7.4 US Market Outlook
7.4.1 US Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.5 Canada Market Outlook
7.5.1 Canada Market Outlook by Value (COVID-19 Impact Recovery Analysis)
7.6 North America Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
7.7 North America Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
7.8 North America Market Outlook by Type (COVID-19 Impact Recovery Analysis)
7.9 North America Market Outlook by Product (COVID-19 Impact Recovery Analysis)
8 Europe Human Microbiome Therapeutics Market
8.1 Europe Market Overview
8.2 Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.3 Europe Market Outlook by Country (COVID-19 Impact Recovery Analysis)
8.4 Russia Market Outlook
8.4.1 Russia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.5 Germany Market Outlook
8.5.1 Germany Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.6 UK Market Outlook
8.6.1 UK Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.7 France Market Outlook
8.7.1 France Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.8 Italy Market Outlook
8.8.1 Italy Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.9 Rest of Europe Market Outlook
8.9.1 Rest of Europe Market Outlook by Value (COVID-19 Impact Recovery Analysis)
8.10 Europe Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
8.11 Europe Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
8.12 Europe Market Outlook by Type (COVID-19 Impact Recovery Analysis)
8.13 Europe Market Outlook by Product (COVID-19 Impact Recovery Analysis)
9 Asia-Pacific Human Microbiome Therapeutics Market
9.1 Asia-Pacific Market Overview
9.2 Asia-Pacific Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.3 Asia-Pacific Market Outlook by Country (COVID-19 Impact Recovery Analysis)
9.4 Japan Market Outlook
9.4.1 Japan Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.5 China Market Outlook
9.5.1 China Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.6 India Market Outlook
9.6.1 India Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.7 South Korea Market Outlook
9.7.1 South Korea Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.8 Australia Market Outlook
9.8.1 Australia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.9 Rest of APAC Market Outlook
9.9.1 Rest of APAC Market Outlook by Value (COVID-19 Impact Recovery Analysis)
9.10 Asia-Pacific Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
9.11 Asia-Pacific Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
9.12 Asia-Pacific Market Outlook by Type (COVID-19 Impact Recovery Analysis)
9.13 Asia-Pacific Market Outlook by Product (COVID-19 Impact Recovery Analysis)
10 LAMEA Human Microbiome Therapeutics Market
10.1 LAMEA Market Overview
10.2 LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.3 LAMEA Market Outlook by Country (COVID-19 Impact Recovery Analysis)
10.4 Brazil Market Outlook
10.4.1 Brazil Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.5 Saudi Arabia Market Outlook
10.5.1 Saudi Arabia Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.6 South Africa Market Outlook
10.6.1 South Africa Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.7 Mexico Market Outlook
10.7.1 Mexico Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.8 UAE Market Outlook
10.8.1 UAE Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.9 Rest od LAMEA Market Outlook
10.9.1 Rest of LAMEA Market Outlook by Value (COVID-19 Impact Recovery Analysis)
10.10 LAMEA Market Outlook by Technology (COVID-19 Impact Recovery Analysis)
10.11 LAMEA Market Outlook by Therapeutics Areas (COVID-19 Impact Recovery Analysis)
10.12 LAMEA Market Outlook by Type (COVID-19 Impact Recovery Analysis)
10.13 LAMEA Market Outlook by Product (COVID-19 Impact Recovery Analysis)
11 Competitive Landscape Analysis
11.1 Investment in Microbiome Therapeutics
11.2 Public Funding Initiatives
11.3 Private Funding Initiatives
11.3.1 Seventure Partners
11.3.2 Flagship Pioneering
11.4 Collaborations and Partnerships in the Global Market
11.5 Licensing and Manufacturing Agreements
11.6 Mergers and Acquisitions in the Global Market
11.7 Leading Market Players in Microbiome Therapeutics Market
11.8 Leading Market Players in Additive Microbiome Therapeutics Market
11.9 Leading Market Players in Modulatory Microbiome Therapeutics Market
11.10 Leading Market Players in Subtractive Microbiome Therapeutics Market
12 Global Human Microbiome Patent Analysis
12.1 Patent Overview
12.2 Patent Analysis
12.3 Patents by Year
12.4 Patents by Type
12.5 Patents by Disease Type
12.6 Patents by Company
12.7 Patents by Country
12.8 Patents by Assignee
13 Global Human Microbiome Clinical Trial Analysis
13.1 Clinical Trial Analysis by Disease Category
13.2 Share of Clinical Trials
13.3 Clinical Trial Analysis by Treatment Strategy
13.4 Share of Clinical Trials
13.5 Clinical Trial Analysis by Company
13.6 Share of Clinical Trials
13.7 Microbiome Therapeutics in Discovery and Preclinical Development
13.8 Microbiome Therapeutics Clinical Trials in Phase 3
14 Leading Company Profiles
14.1 AbbVie Inc. Company
14.1.1 Company Information
14.1.2 Company Overview
14.1.3 Company Financial Profile
14.1.4 Company Product Offerings
14.1.5 Company Recent Developments
14.2 Bristol-Myers Squibb Company
14.2.1 Company Information
14.2.2 Company Overview
14.2.3 Company Financial Profile
14.2.4 Company Product Offerings
14.2.5 Company Recent Developments
14.3 Dow Inc. Chemical Company
14.3.1 Company Information
14.3.2 Company Overview
14.3.3 Company Financial Profile
14.3.4 Company Product Offerings
14.3.5 Company Recent Developments
14.4 Takeda Pharmaceuticals Company Ltd.
14.4.1 Company Information
14.4.2 Company Overview
14.4.3 Company Financial Profile
14.4.4 Company Product Offerings
14.4.5 Company Recent Developments
14.5 Johnson & Johnson Company
14.5.1 Company Information
14.5.2 Company Overview
14.5.3 Company Financial Profile
14.5.4 Company Product Offerings
14.5.5 Company Recent Developments
14.6 DuPont de Nemours, Inc Company
14.6.1 Company Information
14.6.2 Company Overview
14.6.3 Company Financial Profile
14.6.4 Company Product Offerings
14.6.5 Company Recent Developments
14.7 Merck & Co. Inc Company
14.7.1 Company Information
14.7.2 Company Overview
14.7.3 Company Financial Profile
14.7.4 Company Product Offerings
14.7.5 Company Recent Developments
14.8 Pfizer Inc. Company
14.8.1 Company Information
14.8.2 Company Overview
14.8.3 Company Financial Profile
14.8.4 Company Product Offerings
14.8.5 Company Recent Developments
14.9 Vertex Pharmaceuticals Company
14.9.1 Company Information
14.9.2 Company Overview
14.9.3 Company Financial Profile
14.9.4 Company Product Offerings
14.9.5 Company Recent Developments
14.10 Evelo Biosciences, Inc Company
14.10.1 Company Information
14.10.2 Company Overview
14.10.3 Company Financial Profile
14.10.4 Company Product Offerings
14.10.5 Company Recent Developments
14.11 Kaleido Biosciences Inc Company
14.11.1 Company Information
14.11.2 Company Overview
14.11.3 Company Financial Profile
14.11.4 Company Product Offerings
14.11.5 Company Recent Developments
14.12 Seres Therapeutics Inc Company
14.12.1 Company Information
14.12.2 Company Overview
14.12.3 Company Financial Profile
14.12.4 Company Product Offerings
14.12.5 Company Recent Developments
14.13 PureTech Health PLC Company
14.13.1 Company Information
14.13.2 Company Overview
14.13.3 Company Financial Profile
14.13.4 Company Product Offerings
14.13.5 Company Recent Developments
14.14 Nestle S.A. Company
14.14.1 Company Information
14.14.2 Company Overview
14.14.3 Company Financial Profile
14.14.4 Company Product Offerings
14.14.5 Company Recent Developments
14.15 Mayo Clinic Company
14.15.1 Company Information
14.15.2 Company Overview
14.15.3 Company Financial Profile
14.15.4 Company Product Offerings
14.15.5 Company Recent Developments
14.16 MaaT Pharma SA Company
14.16.1 Company Information
14.16.2 Company Overview
14.16.3 Company Financial Profile
14.16.4 Company Product Offerings
14.16.5 Company Recent Developments
14.17 4D Pharma Plc Company
14.17.1 Company Information
14.17.2 Company Overview
14.17.3 Company Financial Profile
14.17.4 Company Product Offerings
14.17.5 Company Recent Developments
14.18 Assembly Biosciences, Inc Company
14.18.1 Company Information
14.18.2 Company Overview
14.18.3 Company Financial Profile
14.18.4 Company Product Offerings
14.18.5 Company Recent Developments
14.19 F. Hoffmann-La Roche Ltd Company
14.19.1 Company Information
14.19.2 Company Overview
14.19.3 Company Financial Profile
14.19.4 Company Product Offerings
14.19.5 Company Recent Developments
14.20 Vedanta Biosciences Company
14.20.1 Company Information
14.20.2 Company Overview
14.20.3 Company Financial Profile
14.20.4 Company Product Offerings
14.20.5 Company Recent Developments
15 Conclusion & Recommendations
16 Glossary
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer